Organs-on-chips: research and commercial perspectives

Drug Discovery Today

Volumn 22, Issue 2, 2017, Pages 397-403

  Balijepalli, Aarathi ^a   Sivaramakrishan, Vaibhav ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DRUG SCREENING; HUMAN; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MICROFLUIDICS; NONHUMAN; ORGANS ON CHIP; REVIEW; TOXICITY; TOXICITY TESTING; ANIMAL; LAB ON A CHIP; TISSUE ENGINEERING;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; LAB-ON-A-CHIP DEVICES; TISSUE ENGINEERING;

EID: 85007134502     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.11.009     Document Type: Review

References (54)

1. 1 Dickson, M., Gagnon, J.P., Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discov. 3 (2004), 417–429.
2. 2 Attarwala, H., TGN1412: from discovery to disaster. J. Young Pharm. 2 (2010), 332–336.
3. 3 Suntharalingam, G., et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006), 1018–1028.
4. 4 Hansen, S., Leslie, R.G., TGN1412: scrutinizing preclinical trials of antibody-based medicines. Nature, 441, 2006, 282.
5. 5 Antoni, D., et al. Three-dimensional cell culture: a breakthrough in vivo. Int. J. Mol. Sci. 16 (2015), 5517–5527.
6. 6 Edmondson, R., et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev. Technol. 12 (2014), 207–218.
7. 7 Breslin, S., O'Driscoll, L., Three-dimensional cell culture: the missing link in drug discovery. Drug Discov. Today 18 (2013), 240–249.
8. 8 Bhatia, S.N., Ingber, D.E., Microfluidic organs-on-chips. Nat. Biotechnol. 32 (2014), 760–772.
9. 9 Caldwell, J., et al. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol. Pathol. 23 (1995), 102–114.
10. 10 Huh, D., et al. Microfabrication of human organs-on-chips. Nat. Protoc. 8 (2013), 2135–2157.
11. 11 Sin, A., et al. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol. Prog. 20 (2004), 338–345.
12. 12 Williamson, A., et al. The future of the patient-specific body-on-a-chip. Lab Chip 13 (2013), 3471–3480.
13. 13 Sung, J.H., et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 13 (2013), 1201–1212.
14. 14 Huh, D., et al. From 3D cell culture to organs-on-chips. Trends Cell Biol. 21 (2011), 745–754.
15. 15 Frantz, C., et al. The extracellular matrix at a glance. J. Cell Sci. 123 (2010), 4195–4200.
16. 16 Sung, J.H., Shuler, M.L., In vitro microscale systems for systematic drug toxicity study. Bioprocess Biosyst. Eng. 33 (2010), 5–19.
17. 17 Li Jeon, N., et al. Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device. Nat. Biotechnol. 20 (2002), 826–830.
18. 18 Cimetta, E., et al. Microfluidic device generating stable concentration gradients for long term cell culture: application to Wnt3a regulation of beta-catenin signaling. Lab Chip 10 (2010), 3277–3283.
19. 19 Voldman, J., et al. Microfabrication in biology and medicine. Annu. Rev. Biomed. Eng. 1 (1999), 401–425.
20. 20 Wang, Z., et al. High-density microfluidic arrays for cell cytotoxicity analysis. Lab Chip 7 (2007), 740–745.
21. 21 Song, J.W., et al. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS One, 4, 2009, e5756.
22. 22 Park, J.W., et al. Microfluidic culture platform for neuroscience research. Nat. Protoc. 1 (2006), 2128–2136.
23. 23 Jang, K.J., Suh, K.Y., A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells. Lab Chip 10 (2010), 36–42.
24. 24 Huh, D., et al. Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 18886–18891.
25. 25 Huh, D., et al. Reconstituting organ-level lung functions on a chip. Science 328 (2010), 1662–1668.
26. 26 Esch, M.B., et al. The role of body-on-a-chip devices in drug and toxicity studies. Annu. Rev. Biomed. Eng. 13 (2011), 55–72.
27. 27 Jones, H.M., et al. Modelling and PBPK simulation in drug discovery. AAPS J. 11 (2009), 155–166.
28. 28 Tatosian, D.A., Shuler, M.L., A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol. Bioeng. 103 (2009), 187–198.
29. 29 Viravaidya, K., et al. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol. Prog. 20 (2004), 316–323.
30. 30 Sung, J.H., Shuler, M.L., A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 9 (2009), 1385–1394.
31. 31 Esch, E.W., et al. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14 (2015), 248–260.
32. 32 Kim, H.J., Ingber, D.E., Gut-on-a-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr. Biol. 5 (2013), 1130–1140.
33. 33 Kim, H.J., et al. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12 (2012), 2165–2174.
34. 34 Kim, H.J., et al. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E7–E15.
35. 35 Lee, H., Cho, D.W., One-step fabrication of an organ-on-a-chip with spatial heterogeneity using a 3D bioprinting technology. Lab Chip 16 (2016), 2618–2625.
36. 36 Toepke, M.W., Beebe, D.J., PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip 6 (2006), 1484–1486.
37. 37 Fox, S., et al. High-throughput screening: update on practices and success. J. Biomol. Screen. 11 (2006), 864–869.
38. 38 Zhang, D., et al. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm. Sin. B. 2 (2012), 549–561.
39. 39 Sambuy, Y., et al. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21 (2005), 1–26.
40. 40 Chen, C.S., et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol. Pharmacol. 65 (2004), 1278–1285.
41. 41 Kimura, H., et al. An on-chip small intestine-liver model for pharmacokinetic studies. J. Lab. Autom. 20 (2015), 265–273.
42. 42 Chao, P., et al. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 78 (2009), 625–632.
43. 43 Rumack, B.H., Matthew, H., Acetaminophen poisoning and toxicity. Pediatrics 55 (1975), 871–876.
44. 44 Imura, Y., et al. Microcirculation system with a dialysis part for bioassays evaluating anticancer activity and retention. Anal. Chem. 85 (2013), 1683–1688.
45. 45 Agarwal, A., et al. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip 13 (2013), 3599–3608.
46. 46 Mathur, A., et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci. Rep., 5, 2015, 8883.
47. 47 Stancescu, M., et al. A phenotypic in vitro model for the main determinants of human whole heart function. Biomaterials 60 (2015), 20–30.
48. 48 Benam, K.H., et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat. Methods 13 (2016), 151–157.
49. 49 Mahler, G.J., et al. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnol. Bioeng. 104 (2009), 193–205.
50. 50 Huh, D., et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci. Transl. Med., 4, 2012, 159ra147.
51. 51 Oleaga, C., et al. Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci. Rep., 6, 2016, 20030.
52. 52 Maschmeyer, I., et al. Chip-based human liver-intestine and liver-skin co-cultures – a first step toward systemic repeated dose substance testing in vitro. Eur. J. Pharm. Biopharm. 95 (2015), 77–87.
53. 53 Loi, C.M., et al. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 37 (1999), 91–104.
54. 54 Mahto, S.K., et al. Microfluidic platforms for advanced risk assessments of nanomaterials. Nanotoxicology 9 (2015), 381–395.